Compare BridgeBio Pharma Inc (BBIO) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Google Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Google Inc trades at $344.67 (market cap $4.36T). The key difference: Google Inc is far larger — about 262.5× BridgeBio Pharma Inc's market cap, and Google Inc pays a 0.25% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | GOOG | |
|---|---|---|
Market Cap | $16.61B | $4.36T |
Sector | Health | Technology |
52-Week High | $90.17 | $399.06 |
52-Week Low | $47.29 | $200.19 |
Enterprise Value | $18.16B | $4.25T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Alphabet (GOOG) trades at $353.47, down 0.88% today, with a bullish technical outlook supported by moving averages and strong support at $352. The company shows robust fundamentals, with 2025 revenue of $402.84B and net income of $132.17B, alongside consecutive earnings beats in recent quarters. Recent news highlights aggressive AI investments and cloud growth, while analyst sentiment remains overwhelmingly positive.
The outlook for GOOG is favorable, driven by AI expansion and cloud revenue growth, with a consensus price target of $431.67 implying significant upside. Risks include high capital expenditures, competitive pressures, and regulatory scrutiny, but strong cash flow and profitability metrics support a bullish investment case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
